HBM HOLDINGS-B (02142) surged over 4% again, trading at HK$14.22 by press time with a turnover of HK$27.85 million, marking a 4.25% gain. The company announced an update and expansion of its global strategic collaboration with AstraZeneca PLC (AZN), initially established in March 2025. Under the enhanced partnership, both parties will leverage their respective expertise to co-develop next-generation biologic therapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs).

Per the agreement, AstraZeneca will nominate R&D projects annually over the next four years, retaining option rights for licensing these programs—a move underscoring the deepening alliance. HBM HOLDINGS-B stands to receive option fees, exercise payments, development/commercial milestone payments, and tiered royalties on future net sales of licensed products. Financial terms align with the framework agreed upon in March 2025.